School of Pharmacy, Binzhou Medical University, Yantai, Shandong, China.
College of Life and Health Science, Northeastern University, Shenyang, China.
Microbiol Spectr. 2024 Apr 2;12(4):e0424723. doi: 10.1128/spectrum.04247-23. Epub 2024 Feb 28.
Cutaneous candidiasis, caused by , is a severe and frustrating condition, and finding effective treatments can be challenging. Therefore, the development of farnesol-loaded nanoparticles is an exciting breakthrough. Ethosomes are a novel transdermal drug delivery carrier that incorporates a certain concentration (10-45%) of alcohols into lipid vesicles, resulting in improved permeability and encapsulation rates compared to conventional liposomes. Farnesol is a quorum-sensing molecule involved in morphogenesis regulation in , and these ethosomes offer a promising new approach to treating this common fungal infection. This study develops the formulation of farnesol-loaded ethosomes (farnesol-ethosomes) and assesses applications in treating cutaneous candidiasis induced by and . Farnesol-ethosomes were successfully developed by ethanol injection method. Therapeutic properties of farnesol-ethosomes, such as particle size, zeta potential, and morphology, were well characterized. According to the results, farnesol-ethosomes demonstrated an increased inhibition effect on cells' growth and biofilm formation in . In Animal infection models, treating farnesol-ethosomes by transdermal administration effectively relieved symptoms caused by cutaneous candidiasis and reduced fungal burdens in quantity. We also observed that ethosomes significantly enhanced drug delivery efficacy and . These results indicate that farnesol-ethosomes can provide future promising roles in curing cutaneous candidiasis.
Cutaneous candidiasis attributed to infection is a prevalent condition that impacts individuals of all age groups. As a type of microbial community, biofilms confer benefits to host infections and mitigate the clinical effects of antifungal treatments. In , the yeast-to-hypha transition and biofilm formation are effectively suppressed by farnesol through its modulation of multiple signaling pathway. However, the characteristics of farnesol such as hydrophobicity, volatility, degradability, and instability in various conditions can impose limitations on its effectiveness. Nanotechnology holds the potential to enhance the efficiency and utilization of this molecule. Treatment of farnesol-ethosomes by transdermal administration demonstrated a very remarkable therapeutic effect against in infection model of cutaneous candidiasis in mice. Many patients suffering fungal skin infection will benefit from this study.
由 引起的皮肤念珠菌病是一种严重且令人沮丧的疾病，寻找有效的治疗方法具有挑战性。因此，法尼醇负载纳米粒的开发是一个令人兴奋的突破。醇质体是一种新型的经皮药物传递载体，将一定浓度（10-45%）的醇类纳入脂质体中，与传统脂质体相比，可提高渗透性和包封率。法尼醇是一种群体感应分子，参与 形态发生的调节，这些醇质体为治疗这种常见的真菌感染提供了一种有前途的新方法。本研究开发了法尼醇负载醇质体（法尼醇醇质体）的配方，并评估了其在治疗 诱导的皮肤念珠菌病中的应用。通过乙醇注入法成功开发了法尼醇醇质体。法尼醇醇质体的治疗特性，如粒径、zeta 电位和形态，得到了很好的表征。结果表明，法尼醇醇质体对 细胞生长和生物膜形成的抑制作用增强。在动物感染模型中，经皮给予法尼醇醇质体治疗可有效缓解皮肤念珠菌病引起的症状，并减少真菌负荷量。我们还观察到，醇质体显著提高了药物的递送效果。这些结果表明，法尼醇醇质体可以在治疗皮肤念珠菌病方面发挥有前途的作用。
由 感染引起的皮肤念珠菌病是一种普遍存在的疾病，影响所有年龄段的人群。作为一种微生物群落，生物膜为宿主感染提供了益处，并减轻了抗真菌治疗的临床效果。在 中，法尼醇通过调节多种信号通路，有效地抑制酵母向菌丝的转变和生物膜的形成。然而，法尼醇的特性，如疏水性、挥发性、降解性和不稳定性，会影响其有效性。纳米技术有可能提高这种分子的效率和利用率。法尼醇醇质体经皮给药治疗对小鼠皮肤念珠菌病感染模型中的 具有非常显著的治疗效果。许多患有真菌性皮肤感染的患者将从这项研究中受益。
